Salesforce (NYSE:CRM – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Macquarie in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $320.00 price target on the CRM provider’s stock. Macquarie’s target price suggests a potential upside of 14.67% from the stock’s previous […]

HC Wainwright reissued their neutral rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a report published on Tuesday morning,Benzinga reports. A number of other brokerages also recently issued reports on PLRX. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $4.00 price objective (down previously from $43.00) on shares of Pliant […]